Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Host factors predicting antibiotic target-site concentrations in critically ill patients
2021-004108-16Phase 4Completed
- Sponsor
- Medical University of Vienna
- Start
- Feb 2022
- Modality
- Small Molecules, Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of daptomycin, meropenem, piperacillin, tazobactam and linezolid in bacterial disease (3 arms), sponsored by Medical University of Vienna. Started Feb 2022; status: completed.
02
Drugs
03
Conditions
bacterial disease
Beyond the preview
Go deeper on 2021-004108-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004108-16.